[{"from": "human", "value": "Provide a description of this molecule. [C][=C][C][=Branch1][=Branch1][=C][N][=C][Ring1][=Branch1][C][=Branch1][C][=O][N][C@@H1][C@H1][Branch2][Branch1][Branch1][C@@H1][Branch2][Ring2][Ring2][C@H1][Branch2][Ring1][C][O][C@H1][Ring1][=Branch1][O][C][=Branch1][C][=O][C][=C][N][=C][C][=C][Ring1][=Branch1][C][O][C][=Branch1][C][=O][C][=C][N][=C][C][=C][Ring1][=Branch1][O][C][=Branch1][C][=O][C][=C][N][=C][C][=C][Ring1][=Branch1][O][C][=Branch1][C][=O][C][=C][N][=C][C][=C][Ring1][=Branch1]"}, {"from": "gpt", "value": "The molecule is a long-acting nicotinic acid derivative with antilipidemic activity. Glunicate has more prolonged activity on plasma free fatty acids and triglycerides, with longer lasting and more intense activity on plasma cholesterol than nicotinic acid or its derivative, niceritrol. In animal models glunicate showed dose-dependent protection of the arterial wall from atheromatous lesions and from cholesterol and collagen accumulation. These effects were independent of its effects on lowering plasma lipid levels."}]